$200mm potential revenue that will only yield $20mm in net income at best.....matters a ton to SNTS at current stock price, but not sure it mattered enough to larger pharma...in fact, probably makes this a $4 or $5 stock vs. a $2 stock
After Zegerid, this makes perfect sense. It fits well with Glumetza. It may do unexpectedly well, but even if it doesn't catch on, I doubt if it will be a complete bomb, since it does drop A1c a bit. Also the climate for a heart safe drug (and probably tho unclaimably heart protective) is probably better than it was a year ago.